Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifarotene Cream 0.005% Bioequivalence Study in Acne Vulgaris
NCT06733402Phase 1Completed
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CD5789 cream vehicle in acne vulgaris (4 arms). Primary endpoints: Therapeutic Equivalence at 12 weeks, Efficacy at 12 weeks and 1 more. Started Jun 2024; status: completed.
02
Drugs
CD5789 cream vehicle
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06733402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733402.